Iris Parent Holding CORP

Liminatus Pharma, Inc. reports stockholder equity exceeding $2.5 million post-merger, awaiting Nasdaq's compliance determination while acknowledging ongoing monitoring.

Liminatus Pharma received a notice from Nasdaq indicating it has not regained compliance with the minimum bid price rule and is not eligible for a second extension, with a decision on continued listing pending.

Liminatus Pharma, Inc. has finalized its acquisition of InnocsAI LLC, amending the merger agreement to include convertible preferred stock as part of the consideration.

Liminatus Pharma announced a warrant exercise inducement offer, resulting in $1.9 million in gross proceeds and the issuance of new warrants.

Liminatus Pharma received a delisting notice from Nasdaq for failing to meet market value requirements, but has requested an appeal.

Liminatus Pharma, Inc. has entered into a definitive merger agreement to acquire InnocsAI LLC in an all-stock transaction valued at approximately $320 million.

Liminatus Pharma reports a net loss of $1.12 million for Q1 2026 while highlighting ongoing efforts to regain Nasdaq compliance.

Liminatus Pharma, a pre-clinical biopharmaceutical company, reported significant losses and a going concern warning in its Q3 2025 filing, despite a recent business combination and capital raise.

Liminatus Pharma, Inc. reported its Q2 2025 results, highlighting its recent Nasdaq listing, significant debt-to-equity conversions, and ongoing going concern doubts despite a net income for the quarter.

Liminatus Pharma, Inc. (formerly Iris Parent Holding Corp.) has successfully completed its business combination, leading to its Nasdaq listing, but the company's financial statements raise substantial doubt about its ability to continue as a going concern.

Liminatus Pharma, Inc. reported a significant increase in net loss for 2025, raising substantial doubt about its going concern ability, and is non-compliant with multiple Nasdaq listing rules.

Valetudo Therapeutics LLC and 1 other reported changes in beneficial ownership of Iris Parent Holding Corp. common stock on July 2, 2026.

Valetudo Therapeutics LLC, a significant shareholder and director of Liminatus Pharma, Inc., transferred a large block of common stock while retaining voting power.

Liminatus Pharma, Inc. is holding its 2026 Annual Meeting of Stockholders on August 3, 2026, to elect directors, ratify auditors, and approve a reverse stock split.

Liminatus Pharma, a pre-clinical stage biopharmaceutical company, is offering up to 6.9 million shares and 10.3 million warrants to fund its CD47 immune checkpoint inhibitor development, despite significant losses and Nasdaq compliance issues.

Liminatus Pharma, a pre-clinical stage biotech, completed its business combination with Iris Acquisition Corp., securing initial funding but still faces significant capital needs and a going concern warning.

Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, has completed its business combination with Iris Acquisition Corp., listing on Nasdaq, but faces substantial doubt about its ability to continue as a going concern due to a history of significant losses and limited cash reserves.

Valetudo Therapeutics LLC and Chris Kim jointly file Schedule 13D, reporting beneficial ownership of 14.3% of Liminatus Pharma's common stock.

Iris Acquisition Holdings LLC has filed a Schedule 13D, revealing a 26.5% beneficial ownership stake in Liminatus Pharma, Inc. following the completion of a business combination.

Valetudo Therapeutics LLC and its CEO, Chris Kim, have filed a Schedule 13D, revealing a significant 23.7% beneficial ownership in Liminatus Pharma, Inc. following the recent business combination.

Samda Biolab Co., Ltd. has reported beneficial ownership of 3,426,548 shares, representing 5.1% of Liminatus Pharma, Inc.'s common stock.

Ewon Comfortech Co., Ltd. has reported beneficial ownership of 5,500,000 shares, representing 10.9% of Liminatus Pharma, Inc.'s common stock, as of June 24, 2026.

KH Feelux Co., Ltd has disclosed a significant 15.4% beneficial ownership stake in Liminatus Pharma, Inc., holding 4,000,000 shares of common stock.

Red Peony Association 1st has reported a beneficial ownership of 5.7% in Liminatus Pharma, Inc., holding 1,470,000 shares of common stock.

Ewon Comfortech Co., Ltd. has disclosed a 5.8% beneficial ownership stake in Liminatus Pharma, Inc., holding 1,500,000 shares of common stock following the consummation of a business combination on April 30, 2025.

Nongae Apple Association 1st has reported a 5.7% passive ownership stake in Liminatus Pharma, Inc. following the consummation of a business combination.